tripartite motif containing 9Genealiases: RNF91 · SPRING
Q-omics provides the consensus-scored TRIM9 profile across patient tissues and cancer cell-line models. TRIM9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRIM9 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TRIM9 RNA expression shows 17,799 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where TRIM9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM9 survival associations across molecular data types. TRIM9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM9 RNA expression–survival associations across cancer types. High TRIM9 expression shows unfavorable associations in BLCA, UVM, MESO, THCA and UCEC, but favorable associations in ACC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRIM9 RNA expression.
This table summarizes TRIM9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM9 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, KIRP, HNSC and LUAD. The KIRC box plot shows higher TRIM9 RNA expression in tumor versus normal tissue (log2 FC = +1.791, t-test p < 0.001).
This table shows molecular features associated with TRIM9 in patient tissues and cancer cell lines. In patient samples, TRIM9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
